JUNO Implodes As ROCKET Is Put On Hold Again, LLY's Expedition Fails

Shares of Eli Lilly & Co. (LLY) were down 10% on Thursday, following the failure of its phase III study of Solanezumab in people with mild dementia due to Alzheimer's disease.

from RTT - Biotech http://ift.tt/2fwQpji
via IFTTT